Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States

Welsh, 1993, Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis, Cell, 73, 1251, 10.1016/0092-8674(93)90353-R Knowles, 2002, Mucus clearance as a primary innate defense mechanism for mammalian airways, J Clin Invest, 109, 571, 10.1172/JCI0215217 Gibson, 2003, Pathophysiology and management of pulmonary infections in cystic fibrosis, Am J Respir Crit Care Med, 168, 918, 10.1164/rccm.200304-505SO MacKenzie, 2014, Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry, Ann Intern Med, 161, 233, 10.7326/M13-0636 Andersen, 1938, Cystic fibrosis of the pancreas and its relation to celiac disease, Am J Dis Child, 56, 344, 10.1001/archpedi.1938.01980140114013 2013 Van Goor, 2009, Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770, Proc Natl Acad Sci U S A, 106, 18825, 10.1073/pnas.0904709106 Yu, 2012, Ivacaftor potentiation of multiple CFTR channels with gating mutations, J Cyst Fibros, 11, 237, 10.1016/j.jcf.2011.12.005 Amaral, 2005, Processing of CFTR: traversing the cellular maze—how much CFTR needs to go through to avoid cystic fibrosis?, Pediatr Pulmonol, 39, 479, 10.1002/ppul.20168 Accurso, 2010, Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation, N Engl J Med, 363, 1991, 10.1056/NEJMoa0909825 Ramsey, 2011, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365, 1663, 10.1056/NEJMoa1105185 Davies, 2013, Efficacy and safety of ivacaftor in patients aged 6 to 11years with cystic fibrosis with a G551D mutation, Am J Respir Crit Care Med, 187, 1219, 10.1164/rccm.201301-0153OC Knudson, 1983, Changes in the normal maximal expiratory flow-volume curve with growth and aging, Am Rev Respir Dis, 127, 725 Bell, 2013, Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have severe lung dysfunction or lung function in the normal range [abstract P8] McCoy, 1996, Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group, Chest, 110, 889, 10.1378/chest.110.4.889 Scheinberg, 2005, A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis, Chest, 127, 1420 Buchdahl, 1988, Increased resting energy expenditure in cystic fibrosis, J Appl Physiol, 64, 1810, 10.1152/jappl.1988.64.5.1810 Rowe, 2014, Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in g551d-mediated cystic fibrosis, Am J Respir Crit Care Med, 190, 175, 10.1164/rccm.201404-0703OC Barry, 2014, Effects of Ivacaftor in cystic fibrosis patients carrying the G551D mutation with severe lung disease, Chest, 146, 152, 10.1378/chest.13-2397 Hebestreit, 2013, Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation, J Cyst Fibros, 12, 599, 10.1016/j.jcf.2013.05.006 Wainwright, 2014, The effect of ivacaftor in individuals with CF and severe lung disease [abstract 442], Pediatr Pulmonol Suppl, 49, 376 Harrison, 2013, Ivacaftor in a G551D homozygote with cystic fibrosis, N Engl J Med, 369, 1280, 10.1056/NEJMc1213681 Polenakovik, 2013, The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (DeltaF508/G551D), J Cyst Fibros, 12, 530, 10.1016/j.jcf.2012.12.004 Lederer, 2009, Obesity and underweight are associated with an increased risk of death after lung transplantation, Am J Respir Crit Care Med, 180, 887, 10.1164/rccm.200903-0425OC